Puma Biotech shares drop more than 20% as European OK of breast cancer drug unlikely


Puma Biotechnology shares dropped 25% to $68 after hours. The company said the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a "negative trend vote" for the drug neratinib to treat early stage HER2-positive breast cancer, meaning it will not likely get approval in a decision scheduled in February, and that additional steps would likely be needed to get a positive approval.



from Biotech News